{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:36:42Z","timestamp":1789997802546,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Simcere Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02729-7","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:21:28Z","timestamp":1749450088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["B7\u2013H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development"],"prefix":"10.1186","volume":"30","author":[{"given":"Weiying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanggeling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"1","key":"2729_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2729_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-981-10-6943-7_7","volume-title":"Management of advanced prostate cancer","author":"HD Yuk","year":"2018","unstructured":"Yuk HD, Kwak C. Role of radical prostatectomy in the management of metastatic prostate cancer. In: Kim CS, editor. Management of advanced prostate cancer. Singapore: Springer; 2018. p. 59\u201363."},{"issue":"17\u201318","key":"2729_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32(17\u201318):1105\u201340.","journal-title":"Genes Dev"},{"issue":"1","key":"2729_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-024-12488-z","volume":"24","author":"X Xu","year":"2024","unstructured":"Xu X, Wang W, He Y, Yao Y, Yang B. Prognostic marker VPS72 could promote the malignant progression of prostate cancer. BMC Cancer. 2024;24(1):713.","journal-title":"BMC Cancer"},{"issue":"4","key":"2729_CR5","first-page":"66","volume":"6","author":"JR Castellanos","year":"2017","unstructured":"Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, Asuthkar S. B7\u2013H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66\u201375.","journal-title":"Am J Clin Exp Immunol"},{"issue":"4","key":"2729_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","volume":"31","author":"S Seaman","year":"2017","unstructured":"Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, et al. Eradication of Tumors through Simultaneous Ablation of CD276\/B7-H3-Positive Tumor Cells and Tumor Vasculature. Cancer Cell. 2017;31(4):501-515.e508.","journal-title":"Cancer Cell"},{"issue":"6","key":"2729_CR7","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3748\/wjg.v21.i6.1804","volume":"21","author":"T Zhang","year":"2015","unstructured":"Zhang T, Jiang B, Zou ST, Liu F, Hua D. Overexpression of B7\u2013H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. 2015;21(6):1804\u201313.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2729_CR8","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3892\/mmr.2015.4050","volume":"12","author":"F Liu","year":"2015","unstructured":"Liu F, Zhang T, Zou S, Jiang B, Hua D. B7\u2013H3 promotes cell migration and invasion through the Jak2\/Stat3\/MMP9 signaling pathway in colorectal cancer. Mol Med Reports. 2015;12(4):5455\u201360.","journal-title":"Mol Med Reports"},{"issue":"1","key":"2729_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2011.09.012","volume":"124","author":"A Brunner","year":"2012","unstructured":"Brunner A, Hinterholzer S, Riss P, Heinze G, Brustmann H. Immunoexpression of B7\u2013H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol. 2012;124(1):105\u201311.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2729_CR10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3892\/or.2016.4607","volume":"35","author":"C Huang","year":"2016","unstructured":"Huang C, Zhou L, Chang X, Pang X, Zhang H, Zhang S. B7\u2013H3, B7\u2013H4, Foxp3 and IL-2 expression in cervical cancer: Associations with patient outcome and clinical significance. Oncol Reports. 2016;35(4):2183\u201390.","journal-title":"Oncol Reports"},{"issue":"11","key":"2729_CR11","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ijc.27566","volume":"131","author":"VA Ingebrigtsen","year":"2012","unstructured":"Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7\u2013H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012;131(11):2528\u201336.","journal-title":"Int J Cancer"},{"issue":"10","key":"2729_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/pin.12999","volume":"70","author":"S Bonk","year":"2020","unstructured":"Bonk S, Tasdelen P, Kluth M, Hube-Magg C, Makrypidi-Fraune G, M\u00f6ller K, H\u00f6flmayer D, Dwertmann Rico S, B\u00fcscheck F, Minner S, et al. High B7\u2013H3 expression is linked to increased risk of prostate cancer progression. Pathol Int. 2020;70(10):733\u201342.","journal-title":"Pathol Int"},{"issue":"1","key":"2729_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/pcan.2016.49","volume":"20","author":"B Benzon","year":"2017","unstructured":"Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, et al. Correlation of B7\u2013H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostat Dis. 2017;20(1):28\u201335.","journal-title":"Prostate Cancer Prostat Dis"},{"key":"2729_CR14","doi-asserted-by":"publisher","first-page":"153303382097164","DOI":"10.1177\/1533033820971649","volume":"19","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang G, Zhang W, Wei X, Hou J, Huang Y. B7\u2013H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis. Technol Cancer Res Treat. 2020;19:1533033820971649.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"2729_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vaccines12010054","volume":"12","author":"IA Koumprentziotis","year":"2024","unstructured":"Koumprentziotis IA, Theocharopoulos C, Foteinou D, Angeli E, Anastasopoulou A, Gogas H, Ziogas DC. New Emerging Targets in Cancer Immunotherapy: The Role of B7\u2013H3. Vaccines (Basel). 2024;12(1):54.","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"2729_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41417-023-00644-9","volume":"30","author":"N Kang","year":"2023","unstructured":"Kang N, Xue H, Lin YY, Dong X, Classen A, Wu R, Jin Y, Lin D, Volik S, Ong C, et al. Influence of ADT on B7\u2013H3 expression during CRPC progression from hormone-naive prostate cancer. Cancer Gene Ther. 2023;30(10):1382\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"2729_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, et al. B7\u2013H3 as a Therapeutic Target in Advanced Prostate Cancer. Eur Urol. 2023;83(3):224\u201338.","journal-title":"Eur Urol"},{"key":"2729_CR18","doi-asserted-by":"publisher","first-page":"994528","DOI":"10.3389\/fcell.2022.994528","volume":"10","author":"J Stanislovas","year":"2022","unstructured":"Stanislovas J, Kermorgant S. c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance. Front Cell Dev Biol. 2022;10:994528.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2729_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","volume":"225","author":"JG Christensen","year":"2005","unstructured":"Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225(1):1\u201326.","journal-title":"Cancer Lett"},{"issue":"2","key":"2729_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12253-011-9430-7","volume":"18","author":"M Gumustekin","year":"2012","unstructured":"Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, Atabey N. HGF\/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res\u202f: POR. 2012;18(2):209\u201318.","journal-title":"Pathol Oncol Res : POR"},{"issue":"9","key":"2729_CR21","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-12-2791","volume":"19","author":"L Goyal","year":"2013","unstructured":"Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF\/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res\u202f: Off J Am Assoc Cancer Res. 2013;19(9):2310\u20138.","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"12","key":"2729_CR22","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.3390\/ijms19123844","volume":"19","author":"M Czyz","year":"2018","unstructured":"Czyz M. HGF\/c-MET signaling in melanocytes and melanoma. Int J Mol Sci. 2018;19(12):3844.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2729_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/cas.12662","volume":"106","author":"R Matsumoto","year":"2015","unstructured":"Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, et al. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF\/c-Met feedback loop. Cancer Sci. 2015;106(6):709\u201317.","journal-title":"Cancer Sci"},{"issue":"7","key":"2729_CR24","doi-asserted-by":"publisher","first-page":"e0134552","DOI":"10.1371\/journal.pone.0134552","volume":"10","author":"YW Kim","year":"2015","unstructured":"Kim YW, Yun SJ, Jeong P, Kim SK, Kim SY, Yan C, Seo SP, Lee SK, Kim J, Kim WJ. The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PloS One. 2015;10(7):e0134552.","journal-title":"PloS One"},{"issue":"2","key":"2729_CR25","first-page":"386","volume":"147","author":"PA Humphrey","year":"1995","unstructured":"Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147(2):386\u201396.","journal-title":"Am J Pathol"},{"issue":"6","key":"2729_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","volume":"60","author":"BS Knudsen","year":"2002","unstructured":"Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60(6):1113\u20137.","journal-title":"Urology"},{"key":"2729_CR27","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1021\/acs.molpharmaceut.4c00330","volume":"21","author":"Q Chang","year":"2024","unstructured":"Chang Q, Huang K, Zou L, Li A, Ye Z, Lin Q, Gu Y. Synthesis and Evaluation of a Novel c-Met-Targeting Cyclic Peptide as a Potential Diagnostic Agent for Colorectal Cancer. Mol Pharm. 2024;21:3613.","journal-title":"Mol Pharm"},{"issue":"6","key":"2729_CR28","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1002\/jcp.26232","volume":"233","author":"N Boromand","year":"2018","unstructured":"Boromand N, Hasanzadeh M, ShahidSales S, Farazestanian M, Gharib M, Fiuji H, Behboodi N, Ghobadi N, Hassanian SM, Ferns GA, et al. Clinical and prognostic value of the C-Met\/HGF signaling pathway in cervical cancer. J Cell Physiol. 2018;233(6):4490\u20136.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2729_CR29","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1007\/s12010-023-04606-7","volume":"196","author":"X Zhu","year":"2024","unstructured":"Zhu X, Shi Y, Wang J. B7\u2013H3 Regulates Glucose Metabolism in Neuroblastom via Stat3\/c-Met Pathway. Appl Biochem Biotechnol. 2024;196(3):1386\u201398.","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"2729_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3892\/etm.2012.764","volume":"5","author":"F Jacobsen","year":"2013","unstructured":"Jacobsen F, Ashtiani SN, Tennstedt P, Heinzer H, Simon R, Sauter G, Sirma H, Tsourlakis MC, Minner S, Schlomm T, et al. High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp Ther Med. 2013;5(1):102\u20136.","journal-title":"Exp Ther Med"},{"issue":"5","key":"2729_CR31","first-page":"1149","volume":"10","author":"K Nakashiro","year":"2003","unstructured":"Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met\/HGF receptor in benign and malignant human prostate tissue. Oncol Reports. 2003;10(5):1149\u201353.","journal-title":"Oncol Reports"},{"key":"2729_CR32","doi-asserted-by":"publisher","first-page":"1372837","DOI":"10.3389\/fimmu.2024.1372837","volume":"15","author":"OE Molina","year":"2024","unstructured":"Molina OE, LaRue H, Simonyan D, Hovington H, Vittrant B, Tetu B, Fradet V, Lacombe L, Bergeron A, Fradet Y. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes. Front Immunol. 2024;15:1372837.","journal-title":"Front Immunol"},{"issue":"22","key":"2729_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI162148","volume":"133","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. J Clin Invest. 2023;133(22):1.","journal-title":"J Clin Invest"},{"issue":"2","key":"2729_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1515\/oncologie-2023-0556","volume":"26","author":"P Cam Pham","year":"2024","unstructured":"Cam Pham P, Van Pham T, Doan Dinh L, Thuan Nguyen L, Le Viet N, Bich Bui M, Quang Nguyen H, Van Pham T, Thuy Thi Vo Q, Binh VuT, et al. BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series. Oncologie. 2024;26(2):247\u201356.","journal-title":"Oncologie."},{"issue":"3","key":"2729_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jncc.2024.05.005","volume":"4","author":"D Zhao","year":"2024","unstructured":"Zhao D, Wang A, Li Y, Cai X, Zhao J, Zhang T, Zhao Y, Dong Y, Zhou F, Li Y, et al. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Cent. 2024;4(3):280\u20137.","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"2729_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.32604\/biocell.2024.048878","volume":"48","author":"C-G Luo","year":"2024","unstructured":"Luo C-G, Zhang J, An Y-Z, Liu X, Li S-J, Zhang WEI, Li KAI, Zhao XU, Yuan D-B, An L-Y, et al. MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression. Biocell. 2024;48(5):771\u201392.","journal-title":"Biocell"},{"key":"2729_CR37","first-page":"e18761429350210","volume":"17","author":"AS Carranza-Aranda","year":"2024","unstructured":"Carranza-Aranda AS, Santerre A, Segura-Cabrera A, Cardenas-Vargas A, Martinez-Velazquez M, Hernandez-Gutierrez R, Herrera-Rodriguez SE. Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer. Curr Mol Pharmacol. 2024;17:e18761429350210.","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"2729_CR38","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12(1):1426.","journal-title":"Nat Commun"},{"issue":"3","key":"2729_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.euo.2023.12.013","volume":"7","author":"H Miyake","year":"2024","unstructured":"Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, et al. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naive Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study. Eur Urol Oncol. 2024;7(3):625\u201332.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"2729_CR40","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323\u201334.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2729_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, Zheng H, Gao X, Wang D, DeLeo AB, et al. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7\u2013H3 CAR T Cells. Mol Cancer Ther. 2021;20(3):577\u201388.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2729_CR42","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","volume":"29","author":"E Shenderov","year":"2023","unstructured":"Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29(4):888\u201397.","journal-title":"Nat Med"},{"issue":"11","key":"2729_CR43","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, et al. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7\u2013H3 for Solid Cancer. Mol Cancer Ther. 2020;19(11):2235\u201344.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2729_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","volume":"22","author":"SN Waqar","year":"2021","unstructured":"Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, et al. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021;22(3):170\u20137.","journal-title":"Clin Lung Cancer"},{"issue":"10275","key":"2729_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","volume":"397","author":"SK Pal","year":"2021","unstructured":"Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695\u2013703.","journal-title":"Lancet"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02729-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:04:31Z","timestamp":1749485071000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02729-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is to certify that the design and methods of the research are in accordance with the requirements of related regulations and procedures (such as GCP and ICH\u2013GCP) as well as the ethical principles. This study was approved by the Institutional Review Board of the Hubei Cancer Hospital (LCKY2024005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"XY. W, HY. L, CX. A and JC. W were employees of SimcereZaiming Pharmaceutical Co., Ltd. at the time of day. Other authors declare no competing financial interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}